Document is current
Any future updates will be listed below
-
Authors
Kaleem, Shayaan
Mihalache, Andrew https://orcid.org/0000-0002-2692-0759
Golrokhian-Sani, Amir-Ali
Lai, Abbie
Zajner, Chris
Popovic, Marko M. https://orcid.org/0000-0002-0370-5968
Kaleem, Sameen
Kertes, Peter J.
Muni, Rajeev H.
Wong, David T.
- License Information
-
More Information
Article History
Received: 7 April 2025
Revised: 21 October 2025
Accepted: 6 November 2025
First Online: 19 December 2025
Competing interests
: MMP: Financial support (to institution) – PSI Foundation, Fighting Blindness Canada. PJK: Honoraria: Novartis, Bayer, Roche, Boehringer Ingelheim, RegenxBio, Apellis; Advisory board – Novartis, Bayer, Roche, Apellis, Novelty Nobility, Viatris, Biogen, AdMare, Kriya Therapeutics; Financial support (to institution) – Roche, Novartis, Bayer, RegenxBio. DTW: Consultant – AbbVie, Alcon, Apellis, Bayer, Bausch Health, Biogen, Boehringer Ingelheim, Novartis, Ripple Therapeutics, Roche, Topcon, Zeiss. Research grants from Novartis, Roche. RHM: Consultant- Alcon,Apellis, AbbVie, Bayer, Bausch Health, Roche; Financial Support (to institution) - Alcon, AbbVie, Bayer, Novartis, Roche.
